Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- distribuição irregular de força nos membros inferiores
- contraturas musculotendinosas nos membros inferiores
- desenvolvimento motor tardio
- hipertrofia da panturrilha
- dificuldade de deambulação e quedas
- tônus muscular e reflexos tendinosos profundos diminuídos
- sensibilidade normal
- sinal de Gower
Outros fatores diagnósticos
- caminhar na ponta dos pés
- hipotonia
- hiperatividade
- incontinência urinária e intestinal
- deficiência intelectual leve a grave
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- creatina quinase (CK) sérica
- teste genético
Investigações a serem consideradas
- eletromiografia (EMG)
- biópsia muscular
- RNM muscular
Algoritmo de tratamento
Colaboradores
Autores
Pinki Munot, MD
Consultant Paediatric Neurologist
Great Ormond Street Hospital for Children
London
UK
Declarações
PM PM is a principal investigator for the Sideros trial in DMD and the ARGNX trial in Myasthenia, and a sub-investigator for the SHINE trial. PM was reimbursed for presenting at the PULSE 65 rare disease day for GPs in December 2023 and for the RCPCH 2022 lunch time symposium by PTC therapeutics.
Agradecimentos
Dr Pinki Munot would like to gratefully acknowledge Dr John R. Bach, Dr Aravindhan Veerapandiyan, and Dr Bilal Saulat, previous contributors to this topic.
Declarações
JRB, AV, and BS declare that they have no competing interests.
Revisores
Lisa D. Hobson-Webb, MD
Assistant Professor of Medicine
Department of Medicine/Neurology
Duke University Medical Center
Durham
NC
Declarações
LDH-W declares that she has no competing interests.
Martin K. Childers, DO, PhD
Associate Professor Neurology and Regenerative Medicine
Wake Forest University Health Sciences
Winston-Salem
NC
Declarações
MKC declares that he has no competing interests.
Adnan Manzur, FRCPCH
Consultant Paediatric Neurologist
Great Ormond Street Hospital for Children NHS Trust
London
UK
Declarações
AM has been paid an honorarium for giving lectures at the Imperial College Educative Training Courses for GPs and post-graduate doctors. AM is the lead author of the Cochrane review of corticosteroids in Duchenne muscular dystrophy. He is also the Lead Clinician of the NorthStar Clinical Network for Management of Neuromuscular Disorders in the UK.
Richard W. Orrell, BSc, MD, FRCP
Senior Lecturer and Consultant Neurologist
Department of Clinical Neuroscience
UCL Institute of Neurology
London
UK
Declarações
RWO is an author of a reference cited in this topic.
Diretrizes
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
- Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
O uso deste conteúdo está sujeito ao nosso aviso legal